PharmaCyte Biotech Cash Flow Statement

Financials in millions USD. Fiscal year is May - April.

Millions USD. Fiscal year is May - Apr.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2016 - 2020
Period Ending	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023	Apr '22 Apr 30, 2022	Apr '21 Apr 30, 2021	2016 - 2020
Net Income	30.66	0.33	-4.32	-4.24	-3.55	Upgrade
Asset Writedown & Restructuring Costs	-	2	-	-	-	Upgrade
Loss (Gain) From Sale of Investments	-26.53	1.57	-	-	-	Upgrade
Stock-Based Compensation	0.48	0.67	0.65	0.11	0.44	Upgrade
Other Operating Activities	-8.94	-7.03	0.17	-	-0.08	Upgrade
Change in Accounts Payable	0.01	0.26	-0.24	0.03	-0.01	Upgrade
Change in Other Net Operating Assets	1.35	0.04	-0.05	-0.02	-0.13	Upgrade
Operating Cash Flow	-2.98	-2.15	-3.79	-4.12	-3.33	Upgrade
Investment in Securities	-7	-	-	-	-	Upgrade
Other Investing Activities	-	-5	-	-	-	Upgrade
Investing Cash Flow	-7	-5	-	-	-	Upgrade
Long-Term Debt Repaid	-	-	-	-0.05	-0.06	Upgrade
Total Debt Repaid	-	-	-	-0.05	-0.06	Upgrade
Net Debt Issued (Repaid)	-	-	-	-0.05	-0.06	Upgrade
Issuance of Common Stock	-	0	0	87.36	4.7	Upgrade
Repurchase of Common Stock	-2.54	-28.2	-13.56	-	-	Upgrade
Financing Cash Flow	-25.03	-10.71	-13.56	87.31	4.64	Upgrade
Foreign Exchange Rate Adjustments	-0	-0	-0.01	0	0	Upgrade
Net Cash Flow	-35.01	-17.86	-17.36	83.2	1.31	Upgrade
Cash Interest Paid	-	-	-	0	0	Upgrade
Cash Income Tax Paid	-	0	-	0	0	Upgrade
Levered Free Cash Flow	-7.99	-2.55	-3.52	-2.62	-1.97	Upgrade
Unlevered Free Cash Flow	-7.99	-2.55	-3.52	-2.62	-1.97	Upgrade
Change in Working Capital	1.36	0.3	-0.3	0.01	-0.15	Upgrade

Updated Aug 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q